Evidence map›Paper›PMID 35604526›Full record

ArticleMolecular imaging and biology2022

Management Impact of Metachronous Oligometastatic Disease Identified on

Redmond-Craig Anderson, Erik M Velez, Hossein Jadvar

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular imaging and biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Oligometastatic Prostate Cancer: Current Status and Future Challenges.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Redmond-Craig AndersonDivision of Nuclear Medicine, Department of Radiology, Keck School of Medicine, University of Southern California, 2250 Alcazar Street, CSC 102, Los Angeles, CA, 90033, USA.
Erik M VelezDivision of Nuclear Medicine, Department of Radiology, Keck School of Medicine, University of Southern California, 2250 Alcazar Street, CSC 102, Los Angeles, CA, 90033, USA.
Hossein JadvarDivision of Nuclear Medicine, Department of Radiology, Keck School of Medicine, University of Southern California, 2250 Alcazar Street, CSC 102, Los Angeles, CA, 90033, USA. jadvar@med.usc.edu.ORCID 0000-0002-9455-2484
University of Southern California · US

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MYLES G COCKBURN · 1985 to 2026
$181.4M
Pilot Human Studies of FMAU PET in Prostate CancerR21EB017568 · NIBIB · UNIVERSITY OF SOUTHERN CALIFORNIA · PI JADVAR, HOSSEIN · 2015 to 2016
$433k
NCI NIH HHS P30 CA014089NIBIB NIH HHS R21 EB017568NIH HHS P30-CA014089NIH HHS R21-EB017568
6 · The paper itself

Abstract

purposeWe assessed the incidence rate and management impact of oligometastatic disease detected on METHODS AND MATERIALS: We retrospectively reviewed our clinical database for men with PCA who underwent

resultsWe identified 21 patients with oligometastases upon first BCR (PSA 0.2-56.8 ng/mL) out of 89 eligible patients. There was a significant difference (p = 0.04) in the mean PSA levels between patients with local recurrence (n = 12) and those without local recurrence (n = 9). In the subgroup of analysis of patients without local recurrence, there was no significant association between mean PSA level and number of oligometastases (p = 0.83). Distribution of oligometastases included 66.7% isolated nodal disease and 33.3% bone only. Twelve (57.1%) patients had change in management to include change in ADT, salvage therapy, or both. Treatment change was initiated in 62.5%, 28.6%, 66.7%, 100%, and 100% of patients with 1, 2, 3, 4, and 5 oligometastatic lesions, respectively.

conclusionThe incidence rate of oligometastatic disease in men with first BCR of PCA undergoing

Indexed as

Positron Emission Tomography Computed TomographyProstatic NeoplasmsCarboxylic AcidsCyclobutanesHumansMaleNeoplasm Recurrence, LocalProstate-Specific AntigenRetrospective StudiesCarboxylic AcidsCyclobutanesfluciclovine F-18Prostate-Specific AntigenCancerFluciclovineOligometastaticProstate

Identifiers

PMID35604526
PMCPMC11927106
OpenAlexW4281398012

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.